US Tech Market Shifts Focus to Smaller Companies Amid Economic Changes

The US techs market has shifted from a bull market dominated by mega-cap tech stocks to favor smaller, lesser-known companies due to economic factors such as a slowing inflation rate. David Kostin, Chief U.S. Equity Strategist at Goldman Sachs, projects a 165% increase in two small-cap firms, RGX-202 and RegenXBio. RegenXBio, a gene therapy company, specializes in single-dose treatments for severe diseases with few or no existing therapies. The company has three drug candidates in its pipeline, with RGX-121 being the most advanced candidate and RGX-202 being investigated for Duchenne muscular dystrophy. The company plans to submit a Biologics License Application later this year, following a pre-BLA meeting with the FDA in June. The company`s Phase I/II AFFINITY DUCHENNE trial is expected to